Genomma Lab Internacional Reports Fourth Quarter and Full Year Results for 2025 Genomma Lab Internacional reveals financial outcomes for Q4 and full year 2025, facing sales declines but maintaining solid operational fundamentals.

Genomma Lab Internacional Reports Fourth Quarter and Full Year Results for 2025 #Mexico #Mexico_City #financial_report #Genomma_Lab #EBITDA_margin

Genomma Lab Internacional Declares a Strong Fourteenth Dividend Payment for Shareholders Genomma Lab Internacional announces its fourteenth dividend payment, showcasing commitment to shareholder value with significant cash distributions.

Genomma Lab Internacional Declares a Strong Fourteenth Dividend Payment for Shareholders #dividends #Mexico #Mexico_City #Stock_Market #Genomma_Lab

Genomma Lab Internacional Reports Third Quarter Results for 2025 Amidst Market Challenges Genomma Lab Internacional has announced its financial results for Q3 2025, highlighting sales challenges due to market conditions and a focus on cost containment.

Genomma Lab Internacional Reports Third Quarter Results for 2025 Amidst Market Challenges #Mexico #Mexico_City #financial_results #Genomma_Lab #EBITDA_margin

Genomma Lab Internacional Reports Second Quarter 2025 Financial Results Genomma Lab Internacional has announced its financial results for Q2 2025, showing growth despite challenges in Argentina and Mexico.

Genomma Lab Internacional Reports Second Quarter 2025 Financial Results #Mexico #Mexico_City #financial_results #Q2_2025 #Genomma_Lab

Genomma Lab Internacional Declares Its Twelfth Dividend Payment to Shareholders Genomma Lab Internacional has announced its twelfth dividend payment, declaring a cash dividend of 0.20 MXN per share, totaling 200 million MXN.

Genomma Lab Internacional Declares Its Twelfth Dividend Payment to Shareholders #dividends #Mexico #Mexico_City #Genomma_Lab #Mexican_Stock_Exchange

Genomma Lab Concludes Full Prepayment of 'LAB 23' Bonds in Mexico Genomma Lab Internacional has successfully completed the early prepayment of its 'LAB 23' unsecured local bonds, enhancing its financial stability and performance.

Genomma Lab Concludes Full Prepayment of 'LAB 23' Bonds in Mexico #Mexico #Mexico_City #pharmaceuticals #Genomma_Lab #LAB_23

Genomma Lab Issues Major Unsecured Bonds to Strengthen Financial Position Genomma Lab Internacional has successfully issued $1.2 billion pesos in unsecured bonds to enhance its financial structure, including early bond amortization.

Genomma Lab Issues Major Unsecured Bonds to Strengthen Financial Position #Mexico #Mexico_City #Genomma_Lab #LAB_25 #LAB_23

Genomma Lab Internacional Reports Strong Q1 2025 Financial Results Fueled by Sales Growth and Productivity Gains Genomma Lab Internacional announces significant growth in Q1 2025, with a 5.0% increase in sales and a remarkable rise in EBITDA, enhancing its market position in the pharmaceutical industry.

Genomma Lab Internacional Reports Strong Q1 2025 Financial Results Fueled by Sales Growth and Productivity Gains #Mexico #Mexico_City #earnings_report #Q1_2025 #Genomma_Lab

Genomma Lab Internacional Declares Its Eleventh Dividend Payment in 2025 Genomma Lab Internacional announces its eleventh dividend of $0.20 MXN per share, totaling $200 million, payable on March 14, 2025.

Genomma Lab Internacional Declares Its Eleventh Dividend Payment in 2025 #Mexico #Mexico_City #dividend_payment #Genomma_Lab

Strong Performance in Genomma Lab's Financial Results for 2024 Genomma Lab Internacional reported impressive financial results for Q4 and the full year 2024, driven by significant growth in sales and profitability across key markets.

Strong Performance in Genomma Lab's Financial Results for 2024 #Mexico #Mexico_City #financial_results #2024 #Genomma_Lab